Tirzepatide Dosage Chart: 0.5mg 3x/Week Protocol

Tirzepatide is a dual GLP-1/GIP receptor agonist. Phase 3 trials (Frias et al., 2021; Jastreboff et al., 2022) documented superior weight loss and glycemic control compared to single-target GLP-1 agonists, with up to 22.5% body weight reduction at 72 weeks in the SURMOUNT-1 trial.

Research-context information only. Tirzepatide is the active ingredient in FDA-approved products for type 2 diabetes and chronic weight management; research-peptide and compounded forms are not FDA-approved and are sold for research purposes only. Protocols, doses, and reactions reported below come from clinical trials and community sources. This article reports what has been documented, not what should be done. Consult a licensed physician for personal medical decisions.

FDA-approved for diabetes and weight management. Research peptide protocols use lower doses than pharmaceutical formulations. This is not medical advice.

The dosing table below carries two labelled row sets. The weekly 2.5-15 mg rows are the FDA-label titration used in the SURMOUNT trials; the 0.25 mg and 0.5 mg 3x/week rows on the 10 mg vial are the community-reported protocol summarised in the Quick Reference.

Quick Reference: Standard Protocol

Self-reported starting doses begin around 0.25 mg 3x weekly for 2-4 weeks to assess tolerance, before increasing to 0.5 mg 3x weekly. Split dosing is described as producing more stable levels than once-weekly injection. For the full tirzepatide profile, vendor pricing, and stacking options, see our tirzepatide peptide page.

Cycling Details

The standard community cycle is 8 weeks on, 8 weeks off. Community sources describe starting conservatively at 0.25 mg 3x weekly (0.75 mg total weekly) for the first 2-4 weeks — the dual GLP-1/GIP mechanism can cause more intense initial GI side effects than single-target agonists.

Community protocols then increase to 0.5 mg 3x weekly (1.5 mg total weekly) when well-tolerated. The split-dosing approach (3x weekly vs once weekly) is described as maintaining more consistent hormone levels and reducing peak-related side effects. Some users self-report continuing until goal weight, then cycling off.

Enhanced Protocol (FDA/Clinical)

Note: The standard protocol above uses research peptide community doses. The FDA-approved protocol below uses significantly higher doses.

Community research peptide protocols use 1.5 mg/week total — roughly 60% of the FDA starting dose and 10% of the maximum. Lower doses still provide meaningful effects with substantially fewer side effects.

Routes of Administration

Subcutaneous (standard and only route): Protocols describe rotating between abdomen, thigh, and upper arm, with abdomen typically providing the most consistent absorption. Community sources describe a 29-31 gauge insulin syringe and the same time each dosing day, morning on an empty stomach preferred.

Reconstitution Quick Reference

Community-documented dilution ratios — full unit conversion math below.

10 mg vial + 2 mL BAC water = 5,000 mcg/mL. A 0.5 mg dose is 10 units on an insulin syringe.

Protocols describe swirling gently, not shaking. Storage is documented as refrigerated at 2–8°C, with use within 28 days.

Ready to buy? Compare verified vendors on our best tirzepatide sources page, or browse all coupon codes for up to 50% off.

Affiliate disclosure: vendor links in this article are affiliate links — The Peptide Catalog may earn a commission if you buy through them, at no additional cost to you.

Where These Numbers Come From

Community protocols use significantly lower doses than FDA-approved protocols, with good rationale.

SURMOUNT-1 Trial (Jastreboff et al., 2022): Even at the 2.5 mg starting dose, participants achieved 16% weight loss. The dual GLP-1/GIP mechanism creates potent metabolic effects at lower doses than single-target agonists.

Head-to-Head vs Semaglutide (Frias et al., 2021): Tirzepatide demonstrated superior glycemic control compared to semaglutide, supporting the dual-agonist advantage.

Research Peptide Variability: Purity and potency vary between suppliers. Starting conservatively accounts for this uncertainty. Individual sensitivity varies — some achieve excellent results well below maximum titration.

Stacking Protocols

Tirzepatide + AOD-9604

Tirzepatide + BPC-157

Stacking with other GLP-1 agonists (semaglutide, liraglutide) is described as redundant — overlapping mechanisms create added side-effect risk without proportional benefit.

Side Effects & Safety

• Nausea — up to 56% at higher FDA doses; much lower at community doses
• Vomiting — up to 36% at high doses
• Diarrhea — 23-26%
• Constipation — 17-19%
• Fatigue — 11-13%
• Pancreatitis risk — trials flagged severe abdominal pain for discontinuation and evaluation
• Gallbladder issues — rapid weight loss increases gallstone risk
• Thyroid C-cell tumors — same boxed warning as semaglutide (animal studies)

GI side effects were more intense than semaglutide in trial data due to the dual mechanism. Slower titration was associated with reduced severity.

mg to Units Conversion

On a standard 100-unit insulin syringe, each "unit" equals 0.01 mL (so 100 units = 1 mL). Once a research-grade compounded tirzepatide vial is reconstituted, the conversion from a target mg dose to syringe units depends entirely on the dilution. The two ratios most often described in community sources are below. Tirzepatide is the active ingredient in FDA-approved products for diabetes and chronic weight management; the FDA-approved formulations are pre-filled and require no syringe math. The conversions below apply to research-grade compounded forms only.

Reconstitution A: 10 mg vial + 2 mL BAC water (5 mg/mL) — the standard "20 units = 1 mg" dilution.

Reconstitution B: 10 mg vial + 1 mL BAC water (10 mg/mL) — half the volume per dose; better for higher-mg draws that would exceed one syringe at 5 mg/mL.

These conversions reflect the dilutions documented in published reconstitution protocols and community sources. They report how reconstitution math is described, not a recommended dosing schedule.